Drug Profile
UD 017
Alternative Names: UD-017Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Ube Industries
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Cancer in Japan
- 02 Jun 2017 Preclinical trials in Cancer in Japan (unspecified route)
- 02 Jun 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)